nectar lifesciences has completed the disposal of its non-core Narbada Industries unit, selling land, structures, and plant machinery to Shree Balaji Cold Chain & Storage Services for a total consideration of ₹11.22 crore. The transaction, finalized on August 04, 2026, removes an inoperative asset from the company’s balance sheet, streamlining operations without impacting core revenue streams. The sale price significantly exceeds the book value of the investment, indicating a potential gain on de-recognition.

The deal was structured in two components: the surrender of leasehold rights for the land and structures situated in Jammu, and the separate sale of plant and machinery located at the premises. Nectar Lifesciences received ₹9.60 crore for the leasehold rights and ₹1.62 crore for the machinery, plus applicable taxes. The company confirmed that Narbada Industries had been inoperative, classifying these assets as non-core. This strategic divestment aligns with efforts to optimize asset utilization by exiting dormant business lines.

Regulatory filings submitted to the National Stock Exchange of India Limited and BSE Limited disclose that the transaction does not constitute a related party transaction. The purchaser, M/s Shree Balaji Cold Chain & Storage Services, is not affiliated with the promoters or group companies of Nectar Lifesciences. The agreement was entered into and completed on August 04, 2026, with all necessary deeds executed on the same date. Sanjaymohan Singh Rawat, Company Secretary & Compliance Officer, signed the disclosure pursuant to Regulation 30 of the SEBI LODR Regulations.

The financial impact of the disposal is minimal in terms of revenue contribution but notable for balance sheet cleanup. During financial year 2025-26, the Narbada Industries unit generated zero revenue, contributing 0.00% to the company’s total income. However, the investment value stood at ₹217.69 lakhs, representing 0.37% of the company’s net worth as of March 31, 2026. The sale proceeds of ₹11.22 crore against a book value of ₹217.69 lakhs suggest a substantial return on the divested capital.

Transaction Details

What the Numbers Show

The disparity between the book value and the sale consideration highlights the latent value in the company’s idle assets. While the Narbada Industries unit contributed no operational revenue, its underlying real estate and equipment held significant market value. By converting this illiquid, non-core investment into cash, Nectar Lifesciences improves its liquidity position without disrupting ongoing pharmaceutical or healthcare operations. The absence of related-party involvement ensures the transaction was conducted at arm's length, validating the commercial fairness of the ₹11.22 crore valuation.

Nectar Lifesciences Limited has extended the timeline for completing the slump sale of its empty hard gelatin capsule business to on or before December 31, 2026. The company announced the extension in a disclosure submitted to the National Stock Exchange of India Limited and BSE Limited on July 23, 2026. The revised deadline reflects a mutual agreement between Nectar Lifesciences and the purchaser, Capnest Health Care Private Limited, to finalize the transaction within the new timeframe.

The slump sale involves the transfer of the company’s empty hard gelatin capsule business as a going concern. This transaction was initially disclosed on December 20, 2025, via letter reference NLL/CS/2025-WFH, with subsequent updates provided on April 28, 2026, under reference NLL/CS/2026-675. The current disclosure, referenced as NLL/CS/2026-697, confirms that while the completion date has shifted, all other relevant terms and disclosures pertaining to the slump sale remain unchanged from the initial announcement.

Transaction Timeline

The company cited Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for making this disclosure. Sanjaymohan Singh Rawat, Company Secretary & Compliance Officer of Nectar Lifesciences Limited, signed the communication. The filing notes that all other relevant disclosures required under the LODR Regulations, as detailed in Annexure 1 to the initial December 2025 letter, continue to hold valid without modification.

What This Means for Shareholders

The extension of the slump sale completion date indicates that the divestment of the empty hard gelatin capsule business will take longer than previously anticipated. For investors, this means the financial impact of the transaction — including any potential proceeds or restructuring benefits — will be realized no earlier than the end of 2026. The mutual agreement suggests that both parties are committed to the deal but require additional time to satisfy regulatory, operational, or legal prerequisites for closing. No changes were reported to the core terms of the sale, implying that the strategic rationale for the divestment remains intact despite the delay.